Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Dexamethasone as Adjuvants to Bupivacaine for ICPB in Thyroidectomy
NCT05793060Phase 4
Key facts
- Status
- Recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- Damanhour Teaching Hospital
- Modality
- Orthosteric Ligands
- Conditions
- postoperative pain
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine and dexamethasone in postoperative pain (2 arms), sponsored by Damanhour Teaching Hospital. Primary endpoint: Numeric Pain Rating Scale at 24 hours. Started Aug 2026; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Group A (n=30)
Bilateral ICPB with isobaric bupivacaine plus dexmedetomidine
Group B (n=30)
Bilateral ICPB with isobaric bupivacaine plus dexamethasone
03
Who it enrols
Adults aged 21-60 with BMI <= 35 undergoing total thyroidectomy, excluding those with significant cardiovascular, respiratory, hepatic, renal, or metabolic comorbidities.
04
Endpoints
Primary
Numeric Pain Rating Scale
Secondary
Drug-related side effects
Beyond the preview
Go deeper on NCT05793060.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05793060.